Antiprotozoal compounds from Mikania periplocifolia (Asteraceae)

Chagas disease, African trypanosomiasis and Leishmaniasis are neglected parasitic diseases which affect millions of people worldwide. In a previous work, we report the antiprotozoal activity of the dichloromethane extract of Mikania periplocifolia Hook. & Arn. (Asteraceae). The aim of this work was to isolate and identify the bioactive compounds present in the extract. The fractionation of the dichloromethane extract has led to the isolation of the sesquiterpene lactone miscandenin and the flavonoid onopordin, together with the sesquiterpene lactones mikanolide, dihydromikanolide and deoxymikanolide, which have previously shown antiprotozoal activity. Miscandenin and onopordin were assayed in vitro against Trypanosoma cruzi, T. brucei and Leishmania braziliensis. Miscandenin was active against T. cruzi trypomastigotes and amastigotes with IC50 values of 9.1 and 7.7 & mu;g/ml, respectively. This sesquiterpene lactone and the flavonoid onopordin showed activity against T. brucei trypo-mastigotes (IC50 = 0.16 and 0.37 & mu;g/ml) and L. braziliensis promastigotes (IC50 = 0.6 and 1.2 & mu;g/ml), respec-tively. The CC50 values on mammalian cells were 37.9 and 53.4 & mu;g/ml for miscandenin and onopordin, respectively. Besides, the pharmacokinetic and physicochemical properties of miscandenin were assessed in silico, showing a good drug-likeness profile. Our results highlight this compound as a promising candidate for further preclinical studies in the search of new drugs for the treatment of trypanosomiasis and leishmaniasis.

Automated summary

This study isolated and identified bioactive compounds, including miscandenin and onopordin, from the dichloromethane extract of Mikania periplocifolia. These compounds showed antiprotozoal activity against Trypanosoma cruzi, T. brucei, and Leishmania braziliensis. Miscandenin in particular exhibited strong antiprotozoal activity. The pharmacokinetic and physicochemical properties of miscandenin were also assessed, demonstrating its potential as a candidate for further preclinical studies.